Atul  Pande net worth and biography

Atul Pande Biography and Net Worth

Director of Immunovant
Dr. Atul Pande M.D. serves as Independent Director of the Company. Since the closing of the Business Combination in December 2019, Dr. Pande has served as a member of Immunovant’s board of directors. Dr. Pande has extensive experience in treatment development across multiple disease areas. He is currently an independent board member of Axovant Gene Therapies, Karuna Therapeutics, Autifony Therapeutics, and Perception Neurosciences. He previously served as the Chief Medical Officer of PureTech Health, Chief Medical Officer of Tal Medical, and medical advisor to PureTech Health. Since April 2014, he has also served as President of Verity BioConsulting, a drug development consulting firm that provides services to clients in the biopharmaceutical business. From 2007 to April 2014, Dr. Pande was Senior Vice President and Senior Advisor, Pharmaceutical R&D at GlaxoSmithKline. He has also held senior roles at Pfizer R&D, Parke-Davis/Warner-Lambert and Lilly Research Laboratories. He has been on the Scientific Advisory Boards of Cennerv Pharma and Centrexion Corporation. Our board of directors believes that Dr. Pande’s medical background and his significant knowledge of the biopharmaceutical industry qualifies him to serve as a member of our board of directors.

What is Atul Pande's net worth?

The estimated net worth of Atul Pande is at least $79,900.00 as of September 1st, 2021. Dr. Pande owns 2,500 shares of Immunovant stock worth more than $79,900 as of March 28th. This net worth evaluation does not reflect any other assets that Dr. Pande may own. Learn More about Atul Pande's net worth.

How do I contact Atul Pande?

The corporate mailing address for Dr. Pande and other Immunovant executives is 320 WEST 37TH STREET, NEW YORK NY, 10018. Immunovant can also be reached via phone at 917-580-3099 and via email at [email protected]. Learn More on Atul Pande's contact information.

Has Atul Pande been buying or selling shares of Immunovant?

Atul Pande has not been actively trading shares of Immunovant within the last three months. Most recently, on Friday, August 13th, Atul Pande bought 5,000 shares of Immunovant stock. The stock was acquired at an average cost of $7.98 per share, with a total value of $39,900.00. Learn More on Atul Pande's trading history.

Who are Immunovant's active insiders?

Immunovant's insider roster includes Peter . (), Eva Barnett (CFO), Julia Butchko (Insider), Douglas Hughes (Director), Mark Levine (Chief Legal Officer and Corporate Secretary), William Macias (Insider), George Migausky (Director), Atul Pande (Director), Peter Salzmann (CEO), and Frank Torti (Director). Learn More on Immunovant's active insiders.

Are insiders buying or selling shares of Immunovant?

During the last twelve months, Immunovant insiders bought shares 1 times. They purchased a total of 1,526,316 shares worth more than $58,000,008.00. During the last twelve months, insiders at the sold shares 29 times. They sold a total of 365,341 shares worth more than $8,607,557.78. The most recent insider tranaction occured on February, 22nd when CFO Eva Renee Barnett sold 2,930 shares worth more than $105,919.50. Insiders at Immunovant own 4.8% of the company. Learn More about insider trades at Immunovant.

Information on this page was last updated on 2/22/2024.

Atul Pande Insider Trading History at Immunovant

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/13/2021Buy5,000$7.98$39,900.00View SEC Filing Icon  
See Full Table

Atul Pande Buying and Selling Activity at Immunovant

This chart shows Atul Pande's buying and selling at Immunovant by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Immunovant Company Overview

Immunovant logo
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
Read More

Today's Range

Now: $31.96
Low: $31.53
High: $32.95

50 Day Range

MA: $35.39
Low: $30.27
High: $40.54

2 Week Range

Now: $31.96
Low: $14.05
High: $45.58

Volume

500,016 shs

Average Volume

1,260,561 shs

Market Capitalization

$4.64 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.67